InnoCan Pharma (HAM:IP40) Institutional Ownership: 0.18% (As of Jul. 11, 2026)


HAM:IP40 InnoCan Pharma Corp HAM:IP40
64 GF Score
Price €1.75
GF Value €7.83
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is InnoCan Pharma Institutional Ownership?

InnoCan Pharma HAM:IP40 64 Institutional Ownership is 0.18% as of Jul. 11, 2026. GuruFocus rates HAM:IP40 with a GF Score™ of 64/100 and a GF Value™ of €7.83 (Possible Value Trap). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, InnoCan Pharma's institutional ownership is 0.18%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, InnoCan Pharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, InnoCan Pharma's Float Percentage Of Total Shares Outstanding is 0.00%.

InnoCan Pharma Institutional Ownership Historical Data

* Premium members only.

The historical data trend for InnoCan Pharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCan Pharma Institutional Ownership Chart

InnoCan Pharma Historical Data

The historical data trend for InnoCan Pharma can be seen below:

2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30 2025-05-31
Institutional Ownership 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18
HAM:IP40
64GF Score
InnoCan Pharma Corp HAM:IP40
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InnoCan Pharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.18% mean?
InnoCan Pharma (HAM:IP40) has a Institutional Ownership of 0.18% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on InnoCan Pharma and its competitors.
Is InnoCan Pharma's Institutional Ownership too high?
InnoCan Pharma's current Institutional Ownership is 0.18%. Overall, InnoCan Pharma has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Institutional Ownership compare to PG and CL?
InnoCan Pharma's Institutional Ownership of 0.18% can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Consumer Packaged Goods company?
A good Institutional Ownership depends on the Consumer Packaged Goods industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on InnoCan Pharma and its competitors. InnoCan Pharma's current Institutional Ownership is 0.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €7.83, compared to a current price of €1.75 — trading 77.7% below its estimated fair value. The current Institutional Ownership is 0.18%. InnoCan Pharma's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current Institutional Ownership is 0.18% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of €1.75 is trading 77.7% below its estimated GF Value™ of €7.83. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for HAM:IP40:

  • Institutional Ownership: 0.18%
  • GF Value™: €7.83 vs. price of €1.75 (77.7% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCan Pharma Business Description

Other Exchanges INNPF:USAINNO:Canada
Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
64GF Score

Get the complete analysis for HAM:IP40

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.75
Price
€7.83
GF Value